Scheelevägen 22
Lund 223 63
Sweden
46 46 19 20 00
https://www.activebiotech.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 8
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Ms. Helen Tuvesson Ph.D. | President & CEO | 4,04M | N/A | 1962 |
Mr. Hans Kolam | Chief Financial Officer | N/A | N/A | 1951 |
Dr. Erik Vahtola | Chief Medical Officer | N/A | N/A | 1976 |
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Active Biotech AB (publ)s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 10. Die grundlegenden Scores sind Audit: 10, Vorstand: 10, Shareholderrechte: 1, Kompensation: 10.